Hair Loss on GLP-1 Drugs: Telogen Effluvium, What Causes It, and When It Stops

"Ozempic hair loss" is one of the most-searched GLP-1 side effect queries — and the experience is real for a meaningful percentage of patients. What is usually not explained is that the drug is not directly damaging hair follicles. The shedding follows a well-understood, temporary biological pattern triggered by the weight loss itself.

This article awaits medical-reviewer signoff.

What is actually happening: telogen effluvium

Scalp hair follicles cycle through three phases:

1. Anagen (active growth): 2–6 years, approximately 85–90% of follicles at any time
2. Catagen (transition): 2–3 weeks
3. Telogen (resting/shedding): 3 months, approximately 10–15% of follicles at any time

In telogen effluvium, a larger proportion of follicles simultaneously enter the telogen phase — triggered by physiological or nutritional stress. Those follicles then shed their hairs 2–4 months later (the delay between the triggering stress and the visible shedding is why it can seem to come "from nowhere").

The visible result: diffuse hair thinning, particularly noticeable when washing hair, brushing, or in the shower drain. Most patients see 2–3x more hair shedding than normal. In severe cases, thinning of the hairline or overall density is visible.

The trigger: rapid weight loss, not the drug

Clinical trials that measured hair loss rates show the pattern clearly:

• STEP 1 (Wegovy, semaglutide 2.4 mg): approximately 3% hair loss in semaglutide arm vs less than 1% in placebo arm
• SURMOUNT-1 (Zepbound, tirzepatide): similar pattern — higher in active treatment arm where substantial weight loss occurred

The critical observation: the placebo arms in these trials — which had minimal weight loss — had minimal hair loss. The hair loss rate correlated with weight loss magnitude, not with drug concentration.

The same pattern of hair shedding occurs after:

• Very low calorie diets
• Bariatric surgery
• Any illness or surgery causing rapid weight loss
• Severe emotional stress or major physiological illness

GLP-1 drugs are associated with hair loss because they produce significant weight loss — not because they directly damage hair follicles.

Nutrient insufficiency as amplifier

Rapid caloric restriction reduces overall nutrient intake. Deficiencies that specifically worsen telogen effluvium:

Protein: The primary building block of hair (keratin). Inadequate protein intake during weight loss is the most commonly cited nutritional contributor to telogen effluvium severity. GLP-1 appetite suppression can inadvertently reduce protein intake when patients self-select towards lower-protein foods.

Iron: Iron deficiency (particularly ferritin below 30–50 ng/mL) is an independent cause of telogen effluvium in women. Patients on restricted intake may not be getting adequate dietary iron. This is worth checking with bloodwork, particularly for premenopausal women.

Zinc: Zinc deficiency impairs hair follicle cell division. Less common than protein or iron deficiency but worth considering.

Biotin: Often marketed specifically for GLP-1-related hair loss. The evidence for biotin supplementation for hair loss is limited to people with actual biotin deficiency — which is uncommon. Biotin has essentially no evidence for hair-loss prevention in biotin-replete individuals. The marketing outpaces the evidence significantly.

What to expect: the timeline

Shedding onset: Typically 2–4 months after the triggering event (significant weight loss beginning). Most patients notice it 2–3 months after meaningful weight loss starts.

Peak shedding: Usually 3–6 months after onset. Daily hair loss may be significantly increased.

Resolution: As weight stabilises and nutrient status normalises, follicles re-enter the anagen phase. The shedding slows and stops. This typically takes 3–6 months from peak shedding.

Regrowth: New hair growth begins as follicles re-enter anagen. It takes another 3–6 months to see meaningful regrowth. Total timeline from first shed to full recovery: approximately 12–18 months in typical cases.

What does not help

Stopping the GLP-1 drug: The hair shedding is from the weight loss that occurred, not from ongoing drug action. Stopping the drug does not immediately stop the shedding (the follicles already in telogen will still shed). Stopping also means resuming the weight-gain trajectory — trading a temporary cosmetic issue for a health outcome.

Topical treatments during the telogen phase: Minoxidil and similar topical treatments are designed for androgenetic alopecia (pattern baldness). They are not specifically indicated for telogen effluvium. Some practitioners use them to accelerate regrowth after the telogen phase, but this is adjunctive rather than curative.

When to see a dermatologist

See a dermatologist if:

• Shedding is patchy rather than diffuse (patchy hair loss has different differential diagnoses, including alopecia areata)
• Shedding continues beyond 12 months with no improvement
• Hair loss is accompanied by scalp scaling, redness, or other symptoms
• You have a personal or family history of androgenetic alopecia (pattern baldness) — these conditions can co-exist and require different management

Editorial note: This article awaits medical-reviewer signoff. Hair loss evaluation is a clinical assessment — dermatological and nutritional evaluation may be appropriate for patients with significant or prolonged shedding.